瑞德西韦与α-干扰素联用治疗新型冠状病毒肺炎的可行性分析

Feasibility Analysis of Remdesivir Combined with Interferon-αin the Treatment of COVID-19

目前尚未发现治疗新型冠状病毒(SARS-CoV-2)肺炎(COVID-19)的特效药。该文总结瑞德西韦和α-干扰素的药理作用及机制,并通过分析COVID-19的流行病学和病原体对两药联合使用治疗COVID-19进行理论探讨。瑞德西韦是一种具有广谱抗病毒作用的核苷类似物,α-干扰素是一种具有广谱抗病毒作用的免疫调节蛋白,二者通过不同机制发挥抗病毒作用,因此二者联合使用或可提高疗效。此外,α-干扰素还可抑制感染部位的炎症反应,因此二者联用既是对因治疗,也是对症治疗。该文旨在为COVID-19的临床用药提供理论依据,但仍需大量的临床试验探索瑞德西韦和α-干扰素联合治疗COVID-19的临床效应。

There is still no specific medicine for novel coronavirus(SARS-CoV-2)pneumonia(COVID-19).Here,we summarized the pharmacology properties and mechanisms of remdesivir and interferon-α,and made a theoretical assessment of the combined use of both drugs in the treatment of COVID-19 through the epidemiology and pathogens analysis of COVID-19.Remdesivir is a nucleoside analogue with a broad-spectrum antiviral effect,and interferon-αis an immune regulatory protein with a broad-spectrum antiviral effect.Both of them exert antiviral effects through different actions,so it is rational to apply them in combination to improve the antiviral effect.In addition,interferon-αexhibits an anti-inflammatory effect at the site of infection,thereby the combination with remdesivir could be used for both etiological and symptomatic treatment of COVID-19.In this article,we provide a theoretical basis for guiding clinical therapy for fighting against COVID-19,although a large amount of clinical trials is still in need of exploring for the clinical use of combining remdesivir and interferon-αin the treatment against COVID-19.